CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 128 enrolled
Drug / intervention
Valbenazine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04102579
NCT04102579Phase 3Completed
CompareCT.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

Neurocrine Biosciences·interventional·Posted Sep 25, 2019·Updated Oct 11, 2023

In Brief

A Phase 3 clinical trial evaluating Valbenazine and Placebo for Chorea, Huntington. Completed, enrolled 128 participants across 46 sites in 2 countries.

Detailed Summary

This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChorea, Huntington
CountriesCanada, United States
CollaboratorsHuntington Study Group

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedSep 25, 2019
Enrollment StartNov 13, 2019
Primary CompletionOct 15, 2021
Study CompletionOct 26, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.8 years ago

Interventions

Valbenazinedrug

vesicular monoamine transporter 2 (VMAT2) inhibitor

Placebodrug

non-active dosage form